

**Date: June 01, 2026**

**To**  
**BSE Limited**  
**25th Floor, PJ Towers**  
**Dalal Street,**  
**Mumbai – 400001**  
**Scrip Code: 524654**

**To**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, C-1, Block G**  
**Bandra Kurla Complex, Bandra (E)**  
**Mumbai – 400051**  
**Symbol: NATCAPSUQ**

**Dear Sir/Madam,**

**Subject: Corrigendum to the Intimation under Regulation 30(9) of SEBI (LODR) Regulations, 2015 dated May 27, 2026.**

This has reference to our intimation under regulation 30(9) of SEBI (LODR) Regulations, 2015 submitted to the Stock Exchanges on May 27, 2026, regarding the Outcome of the Board Meeting of Material Unlisted Subsidiary (i.e. Natural Biogenex Private Limited) detailing the approval of the Rights Issue.

We wish to inform the exchanges that due to a typographical/clerical error, the total number of equity shares for the rights issue was inadvertently mentioned as 11,11,200 instead of 11,11,205.

Consequently, the final revised figures are to be read as follows:

- Corrected Number of Equity Shares being offered in the approved Right Issue: 11,11,205 Equity Shares of Rs. 10/- each.
- Corrected Total Gross Proceeds: Rs. 1,11,12,050/- (Rupees One Crore Eleven Lakh Twelve Thousand and Fifty Only).

All other contents and details specified in the previously published intimation dated May 27, 2026, remain unchanged.

We request you to kindly make this correction on your records and update the same accordingly.

Request to kindly take the same on your records.

**Thanking you,**

**Yours Faithfully,**

**For Natural Capsules Limited**

**Sunil L Mundra**  
**Managing Director**  
**DIN: 00214304**

